EHA 2015: Achieving optimal treatment response in CML through second-generation tyrosine kinase inhibitors - 101793

Spotlight
Video

EHA 2015: Achieving optimal treatment response in CML through second-generation tyrosine kinase inhibitors

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML). Differences in newer TKIs have been observed with clinical trial data suggesting that treatment response to dasatinib and nilotinib is greater than that to the first-generation TKI, imatinib.

—————

The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal. In order to improve the awareness and understanding of hematological malignancies, we are dedicated to providing trusted and up-to-date information.

Website: http://www.vjhemonc.com/...
Twitter: https://twitter.com/VJHemOn...
Facebook: https://www.facebook.com/vj...
LinkedIn: https://www.linkedin.com/co...
Shared By : VJHemOnc
Posted on : 07/29/15
Added : 4 years ago